US 10,441,555 B2 · Pharmaceutical composition

Abstract

The present invention is directed to a pharmaceutical composition comprising a pharmaceutically acceptable carrier and ω-(methylsulfonyl)alkylamine or ω-(methylsulfonyl)alkylamide. The present invention is also directed to a method for treating inflammation, inflammatory-related disorders, or pain, by administering ω-(methylsulfonyl)alkylamine or ω-(methyl sulfonyl)alkylamide, or a pharmaceutically acceptable salt or solvate thereof to a subject in need thereof.

Claims10

Dependent claims

A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound of 3-(methylsulfonyl)propionamide, or a pharmaceutically acceptable salt thereof.

Dependencies are inferred from the claim text.

Facts

Application

15/260,554Filed 9 Sep 2016 · division

Priority

11 Jun 2012

Published

US 2017/0065542 A19 Mar 2017

Granted

15 Oct 2019

Term ends

Not estimatedThe source records don’t support an estimate.

Classification25 codes

A61K 31/16
Medicinal preparations containing organic active ingredients: amides, e.g. hydroxamic acids
A61K 9/0014
Galenical forms characterised by the site of application: skin, i.e. galenical aspects of topical compositions
A61K 9/0053
Galenical forms characterised by the site of application: mouth and digestive tract, i.e. intraoral and peroral administration
A61K 9/06
Medicinal preparations characterised by special physical form: ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels

Family

Application61/658,251Us provisional application · filed 11 Jun 2012

PCT/US2013/044575Parent of this continuation · filed 6 Jun 2013

Application14/562,608Parent of this continuation · filed 5 Dec 2014

Application14/958,165Parent of this division · filed 3 Dec 2015

US 9,205,067 B2Parent of this continuation · filed 8 Dec 2015

US 2017/0065542 A1Pre-grant publication · published 9 Mar 2017

US 9,439,880 B2Parent of this division

Application14/958,165Parent of this continuation

US 2015/0094373 A1Published application

US 2016/0158171 A1Published application

US 10,441,555 B2This patent

From the US filing history. Foreign family members aren’t listed.

Abstract

Facts

Application

15/260,554Filed 9 Sep 2016 · division

Priority

11 Jun 2012

Published

US 2017/0065542 A19 Mar 2017

Granted

15 Oct 2019

Term ends

Not estimatedThe source records don’t support an estimate.

Classification25 codes

A61K 31/16
Medicinal preparations containing organic active ingredients: amides, e.g. hydroxamic acids
A61K 9/0014
Galenical forms characterised by the site of application: skin, i.e. galenical aspects of topical compositions
A61K 9/0053
Galenical forms characterised by the site of application: mouth and digestive tract, i.e. intraoral and peroral administration
A61K 9/06
Medicinal preparations characterised by special physical form: ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels

Family

Application61/658,251Us provisional application · filed 11 Jun 2012

PCT/US2013/044575Parent of this continuation · filed 6 Jun 2013

Application14/562,608Parent of this continuation · filed 5 Dec 2014

Application14/958,165Parent of this division · filed 3 Dec 2015

US 9,205,067 B2Parent of this continuation · filed 8 Dec 2015

US 2017/0065542 A1Pre-grant publication · published 9 Mar 2017

US 9,439,880 B2Parent of this division

Application14/958,165Parent of this continuation

US 2015/0094373 A1Published application

US 2016/0158171 A1Published application

US 10,441,555 B2This patent

From the US filing history. Foreign family members aren’t listed.

Pharmaceutical composition

Life of this patent

Abstract

Claims10

Pharmaceutical composition

Life of this patent

Abstract

Claims10